Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-77c89778f8-sh8wx Total loading time: 0 Render date: 2024-07-16T14:16:49.921Z Has data issue: false hasContentIssue false

Chapter 16 - Management of chronic leukemia in older adults

from Part 3 - Management of hematologic malignancies in older adults

Published online by Cambridge University Press:  05 August 2011

By
Martha Wadleigh  and
Richard Maury Stone
Edited by
Arti Hurria  and
Harvey Jay Cohen
Arti Hurria
Affiliation:
City of Hope Cancer Center, California
Harvey Jay Cohen
Affiliation:
Duke University Medical Center, Durham
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Practical Geriatric Oncology , pp. 230 - 244
Publisher: Cambridge University Press
Print publication year: 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

,National Cancer Institute. SEER Survival Monograph: Cancer Survival among Adults: U.S. SEER Program, 1988–2001, Patient and Tumor Characteristics. Bethesda, MD: National Cancer Institute; 2007.Google Scholar
Dekmezian, R, Kantarjian, HM, Keating, MJ. The relevance of reticulin stain-measured fibrosis at diagnosis in chronic myelogenous leukemia. Cancer. 1987;59(10):1739–1743.3.0.CO;2-2>CrossRefGoogle ScholarPubMed
Buesche, G, Hehlmann, R, Hecker, H. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia – prospective long-term results from a randomized-controlled trial. Leukemia. 2003;17(12):2444–2453.CrossRefGoogle ScholarPubMed
Kantarjian, HM, Dixon, D, Keating, MJ. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer. 1988;61(7):1441–1446.3.0.CO;2-C>CrossRefGoogle ScholarPubMed
Swerdlow, SH, Campo, E, Harris, NL. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.Google Scholar
Rowley, JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243(5405):290–293.CrossRefGoogle ScholarPubMed
Shtivelman, E, Lifshitz, B, Gale, RP. Fused transcript of Abl and Bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550–554.CrossRefGoogle ScholarPubMed
Daley, GQ, Etten, RA, Baltimore, D. Induction of chronic myelogenous leukemia in mice by the P210Bcr/Abl gene of the Philadelphia chromosome. Science. 1990;247(4944):824–830.CrossRefGoogle ScholarPubMed
Li, S, Ilaria Jr, RL, Million, RP. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999;189(9):1399–1412.CrossRefGoogle ScholarPubMed
Druker, BJ, Talpaz, M, Resta, DJ. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.CrossRefGoogle ScholarPubMed
Kantarjian, H, Sawyers, C, Hochhaus, A. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346(9):645–652.CrossRefGoogle ScholarPubMed
O';Brien, SG, Guilhot, F, Larson, RA. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.CrossRefGoogle Scholar
Druker, BJ, Guilhot, F, O';Brien, SG. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355(23):2408–2417.CrossRefGoogle ScholarPubMed
Roy, L, Guilhot, J, Krahnke, T. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood. 2006;108(5):1478–1484.CrossRefGoogle ScholarPubMed
Kantarjian, HM, Talpaz, M, O';Brien, S. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006;108(6):1835–1840.CrossRefGoogle ScholarPubMed
Kantarjian, H, Cortes, J, O';Brien, S. High rates of early major and complete cytogenetic responses with imatinib mesylate therapy given at 400 mg or 800 mg orally daily in patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase [abstract]. Proc Am Soc Clin Oncol. 2002;21:261a.Google Scholar
Baccarani, M, Rosti, G, Castagnetti, F. A comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study. Blood. 2009;113(19):4497–4504.CrossRefGoogle ScholarPubMed
Cortes, J, Baccarani, M, Guilhot, F. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: Tyrosine Kinase Inhibitor Optimization and Selectivity Study. Journal of Clinical Oncology. 2010;28(3):424–430.CrossRefGoogle Scholar
Hehlmann, R, Sausselle, S, Lauseker, M. Randomized comparison of imatinib 400 mg vs. imatinib + INF vs. imatinib + ARAC v. imatinib after INF vs. imatinib 800 mg: optimized treatment and survival. Designed First Interim Analysis of the German CML Study IV. ASH Annu Meet Abstr. 2008;112(11):75.Google Scholar
Guilhot, F, Mahon, FX, Guilhot, J. Randomized comparison of imatinib versus imatinib combination therapies in newly diagnosed chronic myeloid leukaemia (CML) patients in chronic phase (CP): first results of the phase III (SPIRIT) trial from the French CML group (F1 LMC). ASH Annu Meet Abstr. 2008;112(11):74.Google Scholar
Demetri, GD, Mehren, M, Blanke, CD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–480.CrossRefGoogle ScholarPubMed
Cortes, J, Ault, P, Koller, C. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003;101(12):4714–4716.CrossRefGoogle ScholarPubMed
Quintas-Cardama, A, Kantarjian, H, O';Brien, S. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer. 2004;100(12):2592–2597.CrossRefGoogle ScholarPubMed
Cortes, J, O';Brien, S, Quintas, A. Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase. Cancer. 2004;100(11):2396–2402.CrossRefGoogle ScholarPubMed
Cortes, J, Talpaz, M, O';Brien, S. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 2003;98(6):1105–1113.CrossRefGoogle ScholarPubMed
Latagliata, R, Breccia, M, Carmosino, I. Elderly patients with Ph+ chronic myelogenous leukemia (CML): results of imatinib mesylate treatment. Leuk Res. 2005;29(3):287–291.CrossRefGoogle Scholar
Talpaz, M, Silver, RT, Druker, BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002;99(6):1928–1937.CrossRefGoogle ScholarPubMed
Sawyers, CL, Hochhaus, A, Feldman, E. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood. 2002;99(10):3530–3539.CrossRefGoogle ScholarPubMed
O';Hare, T, Walters, DK, Stoffregen, EP. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500–4505.CrossRefGoogle Scholar
Bradeen, HA, Eide, CA, O';Hare, T. Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an n-ethyl-n-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006;108(7):2332–2338.CrossRefGoogle Scholar
McFarland, KL, Wetzstein, GA. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control. 2009;16(2):132–140.CrossRefGoogle ScholarPubMed
Weisberg, E, Manley, P, Mestan, J. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer. 2006;94(12):1765–1769.CrossRefGoogle ScholarPubMed
Weisberg, E, Manley, PW, Breitenstein, W. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7(2):129–141.CrossRefGoogle ScholarPubMed
Golemovic, M, Verstovsek, S, Giles, F. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11(13):4941–4947.CrossRefGoogle ScholarPubMed
Verstovsek, S, Golemovic, M, Kantarjian, H. AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells. Cancer. 2005;104(6):1230–1236.CrossRefGoogle ScholarPubMed
Rosti, G, Castagnetti, F, Poerio, A. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. ASH Annu Meet Abstr. 2008;112(11):181.Google Scholar
Cortes, J, O';Brien, S, Jones, D. Efficacy of nilotinib (formerly AMN107) in patients (Pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. ASH Annu Meet Abstr. 2008;112(11):446.Google Scholar
Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330(12):820–825.CrossRef
Hehlmann, R, Heimpel, H, Hasford, J. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood. 1994;84(12):4064–4077.Google ScholarPubMed
Allan, NC, Richards, SM, Shepherd, PC. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia. Lancet. 1995;345(8962):1392–1397.CrossRefGoogle ScholarPubMed
Ohnishi, K, Ohno, R, Tomonaga, M. A randomized trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase. Blood. 1995;86(3):906–916.Google ScholarPubMed
Randomized study on hydroxyurea alone versus hydroxyurea combined with low-dose interferon-alpha 2b for chronic myeloid leukemia. The Benelux CML Study Group. Blood. 1998;91(8):2713–2721.
Guilhot, F, Chastang, C, Michallet, M. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337(4):223–229.CrossRefGoogle ScholarPubMed
Baccarani, M, Rosti, G, Vivo, A. A randomized study of interferon-alpha versus interferon-alpha and low-dose arabinosyl cytosine in chronic myeloid leukemia. Blood. 2002;99(5):1527–1535.CrossRefGoogle ScholarPubMed
Kluin-Nelemans, HC, Buck, G, Cessie, S. Randomized comparison of low-dose versus high-dose interferon-alfa in chronic myeloid leukemia: prospective collaboration of 3 joint trials by the MRC and HOVON groups. Blood. 2004;103(12):4408–4415.CrossRefGoogle ScholarPubMed
Bonifazi, F, Vivo, A, Rosti, G. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood. 2001;98(10):3074–3081.CrossRefGoogle ScholarPubMed
Berger, U, Engelich, G, Maywald, O. Chronic myeloid leukemia in the elderly: long-term results from randomized trials with interferon alpha. Leukemia. 2003;17(9):1820–1826.CrossRefGoogle ScholarPubMed
Cortes, J, Kantarjian, H, O';Brien, S. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med. 1996;100(4):452–455.CrossRefGoogle ScholarPubMed
Hilbe, W, Apfelbeck, U, Fridrik, M. Interferon-alpha for the treatment of elderly patients with chronic myeloid leukaemia. Leuk Res. 1998;22(10):881–886.CrossRefGoogle ScholarPubMed
Hensley, ML, Peterson, B, Silver, RT. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013. J Clin Oncol. 2000;18(6):1301–1308.CrossRefGoogle ScholarPubMed
Horowitz, MM, Gale, RP, Sondel, PM. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75(3):555–562.Google ScholarPubMed
Kolb, HJ, Schattenberg, A, Goldman, JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–2050.Google ScholarPubMed
Weisser, M, Schleuning, M, Ledderose, G. Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease. Bone Marrow Transplant. 2004;34(12):1083–1088.CrossRefGoogle Scholar
Or, R, Shapira, MY, Resnick, I. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood. 2003;101(2):441–445.CrossRefGoogle ScholarPubMed
Kebriaei, P, Detry, MA, Giralt, S. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood. 2007;110(9):3456–3462.CrossRefGoogle ScholarPubMed
Crawley, C, Szydlo, R, Lalancette, M. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005;106(9):2969–2976.CrossRefGoogle ScholarPubMed
Jemal, A, Siegel, R, Ward, E. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71–96.CrossRefGoogle ScholarPubMed
Cheson, BD, Bennett, JM, Grever, M. National Cancer Institute–sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990–4997.Google Scholar
Eichhorst, B, Hallek, M. Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). Best Pract Res Clin Haematol. 2007;20(3):469–477.CrossRefGoogle Scholar
Hallek, M, Cheson, BD, Catovsky, D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood. 2008;111(12):5446–5456.CrossRefGoogle ScholarPubMed
Hercher, C, Robain, M, Davi, F. A multicentric study of 41 cases of B-prolymphocytic leukemia: two evolutive forms. Leuk Lymphoma. 2001;42(5):981–987.CrossRefGoogle ScholarPubMed
Seam, P, Juweid, ME, Cheson, BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507–3516.CrossRefGoogle ScholarPubMed
Rozman, C, Montserrat, E, Rodriguez-Fernandez, JM. Bone marrow histologic pattern – the best single prognostic parameter in chronic lymphocytic leukemia: a multivariate survival analysis of 329 cases. Blood. 1984;64(3):642–648.Google ScholarPubMed
Binet, JL, Auquier, A, Dighiero, G. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198–206.3.0.CO;2-V>CrossRefGoogle ScholarPubMed
Rai, KR, Sawitsky, A, Cronkite, EP. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219–234.Google ScholarPubMed
Rawstron, AC, Bennett, FL, O';Connor, SJ. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575–583.CrossRefGoogle ScholarPubMed
Crespo, M, Bosch, F, Villamor, N. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med. 2003;348(18):1764–1775.CrossRefGoogle ScholarPubMed
Wiestner, A, Rosenwald, A, Barry, TS. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood. 2003;101(12):4944–4951.CrossRefGoogle ScholarPubMed
Damle, RN, Wasil, T, Fais, F. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94(6):1840–1847.Google ScholarPubMed
Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. J Natl Cancer Inst. 1999;91:861–868.CrossRef
Hamblin, TJ. Autoimmune complications of chronic lymphocytic leukemia. Semin Oncol. 2006;33(2):230–239.CrossRefGoogle ScholarPubMed
Rai, KR, Peterson, BL, Appelbaum, FR. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750–1757.CrossRefGoogle ScholarPubMed
Byrd, JC, Peterson, BL, Morrison, VA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101(1):6–14.CrossRefGoogle Scholar
Byrd, JC, Rai, K, Peterson, BL. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood. 2005;105(1):49–53.CrossRefGoogle ScholarPubMed
Hillmen, P, Skotnicki, AB, Robak, T. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol. 2007;25(35):5616–5623.CrossRefGoogle ScholarPubMed
Knauf, WU, Lissichkov, T, Aldaoud, A. Bendamustine versus chlorambucil in treatment-naive patients with B-cell chronic lymphocytic leukemia (B-CLL): results of an international phase III study [abstract]. ASH Annu Meet Abstr. 2007;110(11):2043.Google Scholar
Keating, MJ, O';Brien, S, Albitar, M. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–4088.CrossRefGoogle ScholarPubMed
Wierda, W, O';Brien, S, Wen, S. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4070–4078.CrossRefGoogle ScholarPubMed
Flinn, IW, Neuberg, DS, Grever, MR. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol. 2007;25(7):793–798.CrossRefGoogle ScholarPubMed
Grever, MR, Lucas, DM, Dewald, GW. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol. 2007;25(7):799–804.CrossRefGoogle ScholarPubMed
Weiss, MA, Maslak, PG, Jurcic, JG. Pentostatin and cyclophosphamide: an effective new regimen in previously treated patients with chronic lymphocytic leukemia. J Clin Oncol. 2003;21(7):1278–1284.CrossRefGoogle ScholarPubMed
Lamanna, N, Kalaycio, M, Maslak, P. Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. J Clin Oncol. 2006;24(10):1575–1581.CrossRefGoogle ScholarPubMed
Kay, NE, Geyer, SM, Call, TG. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood. 2007;109(2):405–411.CrossRefGoogle ScholarPubMed
Keating, MJ, Flinn, I, Jain, V. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99(10): 3554–3561.CrossRefGoogle ScholarPubMed
Stilgenbauer, S, Dohner, H. Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. N Engl J Med. 2002;347(6):452–453.CrossRefGoogle ScholarPubMed
O';Brien, SM, Keating, MJ, Mocarski, ES. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab. Clin Lymphoma Myeloma. 2006;7(2):125–130.CrossRefGoogle Scholar
Sorror, ML, Maris, MB, Sandmaier, BM. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23(16):3819–3829.CrossRefGoogle ScholarPubMed
,Non Hodgkin's lymphoma. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http://www.nccn.org/index.asp
O';Brien, S.New agents in the treatment of CLL. Hematol Am Soc Hematol Educ Prog. 2008;2008:457–464.Google Scholar
Goldman, JM. How I treat chronic myeloid leukemia in the imatinib era. Blood. 2007;110(8):2828–2837.CrossRefGoogle Scholar
,Chronic myelogenous leukemia. In: National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. http://www.nccn.org/index.asp
Dohner, H, Stilgenbauer, S, Benner, A. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–1916.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×